drugset / Trial / NCT06138795

A Single and Multiple Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2389 in Healthy Participants

NCT06138795

Phase 1 Completed 120 enrolled AstraZeneca
RandomizedSequentialSingle-blindTreatment

Summary

This study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD2389 following single and multiple dose administration (SAD/MAD) to healthy participants.

Timeline

Start
2023-11-20
Primary completion
2025-08-24
Completion
2025-08-24

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD2389 Small molecule Oral

Indications

No indication recorded.